吉西他滨联合奈达铂治疗晚期非小细胞肺癌的临床观察  

Gemcitabine Combined with Nedaplatin in the Treatment of Advanced Non-small Cell lung Cancer

作　　者：兰四友[1,2] 张德芬[1,2] 邓述恺[1,2] 王荣丽[1,2] 杨小琼[1,2] 

机构地区：[1]泸州医学院附属医院呼吸内科,四川泸州646000 [2]泸州医学院附属医院急诊科,四川泸州646000

出　　处：《四川医学》2014年第6期703-705,共3页Sichuan Medical Journal

摘　　要：目的：观察吉西他滨（ GEM）联合奈达铂（ NDP）组成的GN方案治疗晚期非小细胞肺癌（ NSCLC,Non-small cell lung cancer ）的疗效和安全性。方法65例NSCLC患者采用GN方案：GEM1000-1250mg/m^2,第1、8d静脉滴注, NDP 80-90mg/m^2,第1d 静脉滴注,28d 为1周期。结果全组65例中,完全缓解5例（7．69%）,部分缓解22例（33．85%）,稳定28例（43．08%）,进展10例（15．38%）,客观缓解率为41．54%,疾病控制率84．62%。主要不良反应为骨髓抑制,经对症处理后可以缓解,无治疗相关死亡。结论国产吉西他滨联合奈达铂治疗晚期NSCLC疗效较好,不良反应轻。Objective To observe the efficacy and the side-effects of gemcitabine （ GEM ） combined with nedaplatin （NDP） in the treatment of advanced non -small cell lung cancer（NSCLC）. Methods 65 patients with NSCLC were treat with gemcitabine （GEM 1000-1250mg/m^2,ivdrip,d1,d8） plus nedaplatin （NDP 80-90mg/m^2,ivdrip,d1）,every 28 days. Results Five patients out of 65 were complete response,22 patients were partial response,28 patients were stable,10 patients were progressive. The objective response rate was 41. 54%, and disease control rate was 84. 62%. The main side-effect was myelosuppression,and no patient was dead in the treatment. Conclusion Domestic gemcitabine plus nedaplatin was an effective treatment with less side-effects.

关 键 词：吉西他滨 奈达铂 晚期 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]